A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis (NIBIT-M2)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02460068 |
Recruitment Status : Unknown
Verified May 2015 by Italian Network for Tumor Biotherapy Foundation.
Recruitment status was: Recruiting
First Posted : June 2, 2015
Last Update Posted : June 2, 2015
|
Sponsor:
Italian Network for Tumor Biotherapy Foundation
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Italian Network for Tumor Biotherapy Foundation
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Unknown |
---|---|
Estimated Primary Completion Date : | January 2018 |
Estimated Study Completion Date : | January 2020 |
Publications: